BioCentury | Jul 14, 2017
Clinical News

Alnylam, Sanofi start Phase III program of fitusiran for hemophilia

...about 100 patients with hemophilia A or B without inhibitors receiving prior on-demand therapy. The ATLAS-PPX...
...B with or without inhibitors receiving prophylaxis therapy as prior standard of care (SOC). In ATLAS-PPX...
BioCentury | Oct 13, 2016
Distillery Therapeutics

Therapeutics: E. coli exopolyphosphatase (PPX)

...PPX could help treat thrombosis. In human and mouse platelet-rich plasma-based clotting assays, E. coli PPX...
...in vitro model of thrombus formation using mouse or human blood under flow, E. coli PPX...
...Next steps could include testing the safety of E. coli PPX in animal models. TARGET/MARKER/PATHWAY: E. coli exopolyphosphatase (PPX)...
BioCentury | Dec 19, 2005
Clinical News

PRX302: IND submitted

PPX submitted an IND to begin an open-label, dose-escalation, U.S. Phase I trial in 18 to 24 patients. Protox Therapeutics Inc. (TSX-V:PRX), Vancouver, B.C. Product: PRX302 Business: Cancer Molecular target: Not available Description: Pore-forming prodrug...
Items per page:
1 - 3 of 3